AS
Therapeutic Areas
Foghorn Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FHD-286 | Relapsed/Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) | Phase 1 |
| FHD-609 | Synovial Sarcoma and SMARCB1-deleted Tumors | Phase 1 |
| FVH-286 | Ophthalmology (e.g., Geographic Atrophy) | Preclinical |
| BRM Selective Program | Undisclosed Oncology | Discovery |
Leadership Team at Foghorn Therapeutics
AG
Adrian Gottschalk, J.D.
President and Chief Executive Officer
CK
Cigall Kadoch, Ph.D.
Co-Founder, Scientific Advisory Board Chair, and Director
GC
Gerald Crabtree, M.D.
Co-Founder and Director
SA
Samuel Agresta, M.D., M.P.H.
Chief Medical Officer
ML
Michael LaCascia, J.D.
Chief Business Officer
AB
Allison Burr, J.D.
Executive Vice President, Corporate Affairs & General Counsel
JM
Joel Marcus
Executive Chairman and Chairman of the Board
SB
Steven Bellon, Ph.D.
Chief Technology Officer
KS
Katherine S. Bowdish, Ph.D.
Director
WK
William K. Heiden
Director